Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.94 |
| ▸ | CA1 | P00915 | 4/20 | 0.94 |
| ▸ | CA2 | P00918 | 4/20 | 0.94 |
| ▸ | CA7 | P43166 | 4/20 | 0.94 |
| ▸ | CA9 | Q16790 | 4/20 | 0.94 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | CA4 | P22748 | 3/20 | 0.94 |
| ▸ | CA6 | P23280 | 3/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.94 |
| ▸ | CA3 | P07451 | 2/20 | 0.94 |
| ▸ | CA5A | P35218 | 2/20 | 0.94 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | SELL | P14151 | 1/20 | 0.94 |
| ▸ | HPGD | P15428 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallic Acid SCHEMBL27958244 | 0.97 | CA12 (0.90) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL9398055 | 0.97 | CA12 (0.90) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL29484566 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL678990 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL15012 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL30375631 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL4918056 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL8088102 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1845406 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Gallic Acid SCHEMBL1738964 | 0.94 | CA12 (0.94) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539278-B2 | Nanocomposite particle and uses thereof | ACADEMIA SINICA (TW) | 2026-02-03 | — | — | US | claimed |
| US-12515067-B2 | Non-invasive systems and methods for selective activation of photoreactive responses | IMMUNOLIGHT, LLC (US) | 2026-01-06 | — | — | US | claimed |
| CN-119352160-B | Rare earth doped yttrium gallate laser material and preparation method and application thereof | 中国科学院合肥物质科学研究院 | 2025-03-11 | — | — | CN | claimed |
| CN-119352160-A | Rare earth doped yttrium gallate laser material and preparation method and application thereof | 中国科学院合肥物质科学研究院 | 2025-01-24 | — | — | CN | claimed |
| EP-3367890-B1 | A PHOTOACTIVATABLE DRUG FOR USE IN RADIOTHERAPY | IMMUNOLIGHT LLC (US) | 2024-12-04 | — | — | EP | claimed |
| US-11981846-B2 | Nanocomposite and uses thereof | ACADEMIA SINICA (TW) | 2024-05-14 | — | — | US | claimed |
| US-11786595-B2 | Methods for radiotherapy to trigger light activation drugs | IMMUNOLIGHT, LLC (US) | 2023-10-17 | — | — | US | claimed |
| US-20230109074-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR SELECTIVE ACTIVATION OF PHOTOREACTIVE RESPONSES | IMMUNOLIGHT, LLC (US) | 2023-04-06 | — | — | US | claimed |
| US-11534622-B2 | Non-invasive systems and methods for selective activation of photoreactive responses | IMMUNOLIGHT, LLC (US) | 2022-12-27 | — | — | US | claimed |
| US-20220257524-A1 | NANOCOMPOSITE PARTICLE AND USES THEREOF | ACADEMIA SINICA (TW) | 2022-08-18 | — | — | US | claimed |
| WO-2008130562-A1 | COMPOSITIONS COMPRISING ORGANIC AND INORGANIC PHOSPHORS FOR CONVERTING ELECTROMAGNETIC RADIATION AND METHODS FOR USING THE SAME | BERNSTEIN ERIC F (US) | 2008-10-30 | — | — | WO | claimed |
| US-20060269483-A1 | SEM cathodoluminescent imaging using up-converting nanophosphors | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2006-11-30 | — | — | US | claimed |
| WO-2006093966-A2 | SEM CATHODOLUMINESCENT IMAGING USING UP-CONVERTING NANOPHOSPHORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2006-09-08 | — | — | WO | claimed |
| WO-2006017140-A2 | METHODS FOR OPTICALLY ENCODING AN OBJECT WITH UPCONVERTING MATERIALS AND COMPOSITIONS USED THEREIN | PARALLEL SYNTHESIS TECHNOLOGIES, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050136486-A1 | Upconverting phosphors for use as signaling entities conjugated on optically encoded objects; optical barcodes | PARALLEL SYNTHESIS TECHNOLOGIES, INC. | 2005-06-23 | — | — | US | claimed |
| US-20030207331-A1 | Encoding methods using up-converting phosphors for high-throughput screening of catalysts | SRI INTERNATIONAL | 2003-11-06 | — | — | US | claimed |
| US-6537829-B1 | Phosphorescent, fluorescent labels; detectable labels, bioassays for detecting soluble, suspended, particulate substances; use in performing sensitive detection of analytes, such as biological macromolecules | SRI INTERNATIONAL | 2003-03-25 | — | — | US | claimed |
| US-6399397-B1 | TRANSPORTATING, CAPTURING LIQUID SAMPLE, LABELING WITH PHOSPHORS | SRI INTERNATIONAL | 2002-06-04 | — | — | US | claimed |
| US-20020045190-A1 | Encoding methods using up-converting phosphors for high-throughput screening of catalysts | SRI INTERNATIONAL | 2002-04-18 | — | — | US | claimed |
| WO-2002004527-A2 | ENCODING METHODS USING UP-CONVERTING PHOSPHORS FOR HIGH-THROUGHPUT SCREENING OF CATALYSTS | SRI INTERNATIONAL (US) | 2002-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786595-B2 | Methods for radiotherapy to trigger light activation drugs | MTNR1A, ATM, CHUK | CA12 1742/4885CA1 986/4885CA2 584/4885 |
| US-12539278-B2 | Nanocomposite particle and uses thereof | SGMS2, SGMS1, PHOSPHO1 | CA12 480/4885CA1 739/4885CA2 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.